

Date of preparation: 13 April 2026

Issuer's abbreviated name: SYN2BIO SA

Current report: 9/2026 ESPI

Subject: Estimated value of the amount of financing transferred as part of the Demerger

Legal basis: Article 17 section 1 of the MAR Regulation - inside information

Body of the report:

Time of publication: 1:10 p.m.

In reference to the information set forth in item 8.3. (Third Registration Document) of the Issuer's Prospectus approved by the Polish Financial Supervision Authority on 12 March 2026 concerning the amount of financing transferred to the Issuer as part of the Demerger, and to the information ensuing from Synektik S.A.'s Demerger Plan of 23 July 2025 (Attachment 7 item 5B to the Demerger Plan), the Management Board of SYN2BIO S.A. with its registered office in Warsaw ("Issuer") reports that the Issuer's estimated net asset value as of 27 March 2026 (date of registration of the Demerger) has been rounded to PLN 43.1 million, of which the estimated value of the cash has been rounded to PLN 25.9 million.

Representatives of the Issuer:

Cezary Kozanecki - President of the Management Board